Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

BlossomHill Therapeutics Q3 2026 Results: Net Loss of $24M, Loss Widens

BlossomHill Therapeutics is a clinical-stage biopharmaceutical company with two product candidates, BH-30643 and BH-30236, in early clinical development and one preclinical candidate, BH-501284. The company has incurred substantial losses since inception and anticipates continued losses as it advances its precision medicine programs for genetically defined cancers.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-24.0-16.0
EPS (diluted, $ a share)$-1.29$-6.54

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: BLSM. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

BlossomHill Therapeutics, Inc.: key numbers

Share price
$15.13Close, Nov 17
Market cap
$481M
Shares outstanding
31.78MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from BlossomHill Therapeutics, Inc.

All →
4:16 PM ET 8-K
Financial Results

BlossomHill Therapeutics Financial Results

BlossomHill Therapeutics reported third quarter 2026 financial results, ending the period with $224.9 million in cash and cash equivalents. The company aligned with the FDA on a Phase 2 dose for BH-30643 and plans to initiate the pivotal SOLARA-2 trial in Q1 2027 for patients with EGFR C797S-positive NSCLC.

Term
Q3 2026

“We are pleased to have aligned with the FDA on a recommended Phase 2 dose of 50 mg BID based on favorable PK, safety and efficacy data in the Phase 1 portion of the SOLARA trial. We are now preparing to initiate SOLARA-2, a single arm, pivotal Phase 2 trial designed to evaluate BH-30643 in both chemotherapy-naive and chemotherapy-pretreated patients with C797S-positive NSCLC after progression on a third-generation EGFR TKI.”

J. Jean Cui, Ph.D., Founder, President and Chief Executive Officer
7:15 AM ET 8-K
Financial Results

BlossomHill Therapeutics Financial Results

BlossomHill Therapeutics reported financial results for the second quarter of 2026, highlighting the successful completion of its $168.3 million IPO in August. The company also noted clinical progress for BH-30643, which received FDA Fast Track designation for the treatment of advanced EGFR C797S-positive NSCLC.

Term
Q2 2026

“We’ve achieved meaningful progress across our pipeline, as well as our significant corporate milestones, since the beginning of the second quarter. In April, we presented our first preclinical data from our pseudo-irreversible pan-KRAS inhibitor BH-501284, built on a novel chemical scaffold, at AACR where we highlighted the sustained target engagement leading to tumor regression at low dose levels.”

Jean Cui, Ph.D., Founder, President and Chief Executive Officer

“With a strong balance sheet following our successful initial public offering in August, we believe we are well positioned to deliver important clinical and regulatory milestones over the coming quarters as we continue advancing our intentionally designed medicines that address significant unmet medical needs in cancer treatment.”

Jean Cui, Ph.D., Founder, President and Chief Executive Officer
7:30 AM ET 8-K
Clinical Trial Data

BlossomHill Therapeutics Clinical Trial Data

BlossomHill Therapeutics announced updated Phase 1/2 SOLARA trial data for BH-30643 in patients with EGFR C797S-positive NSCLC, showing a 45% objective response rate and 88% disease control rate. The results, presented at the 2026 World Conference on Lung Cancer, demonstrate the drug's potential to overcome resistance to existing EGFR inhibitors in a population with no approved targeted therapies. The company plans to advance the candidate into a Phase 2 trial in 2027 following its recent FDA Fast Track designation.

Counterparty
International Association for the Study of Lung Cancer (IASLC)

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.